GlobeNewswire
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
📈
AI Sentiment
Highly Positive
8/10
- Home
- NOTV
NOTV
Inotiv Inc.
as of 12-15-2025 12:26pm EST
$0.69
$0.08
-10.22%
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Chart Type:
Time Range:
| Founded: | 1974 | Country: | United States |
| Employees: | N/A | City: | WEST LAFAYETTE |
| Market Cap: | 29.9M | IPO Year: | 1997 |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $6.48 | Next Earning Date: | 02-04-2026 |
| Revenue: | $513,024,000 | Revenue Growth: | 4.54% |
| Revenue Growth (this year): | 6.26% | Revenue Growth (next year): | 45.49% |
AI-Powered NOTV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 72.85%
72.85%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Inotiv Inc. (NOTV)
Neff R Matthew
Sell
Director
NOTV Dec 1, 2025
Avg Cost/Share
$0.89
Shares
2,000
Total Value
$1,770.60
Owned After
151,102
SEC Form 4
Neff R Matthew
Sell
Director
NOTV Nov 3, 2025
Avg Cost/Share
$1.24
Shares
2,000
Total Value
$2,486.80
Owned After
151,102
SEC Form 4
Neff R Matthew
Sell
Director
NOTV Oct 1, 2025
Avg Cost/Share
$1.43
Shares
2,000
Total Value
$2,857.80
Owned After
151,102
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Neff R Matthew | NOTV | Director | Dec 1, 2025 | Sell | $0.89 | 2,000 | $1,770.60 | 151,102 | |
| Neff R Matthew | NOTV | Director | Nov 3, 2025 | Sell | $1.24 | 2,000 | $2,486.80 | 151,102 | |
| Neff R Matthew | NOTV | Director | Oct 1, 2025 | Sell | $1.43 | 2,000 | $2,857.80 | 151,102 |
Latest Inotiv Inc. News
NOTV Breaking Stock News: Dive into NOTV Ticker-Specific Updates for Smart Investing
Compare NOTV vs Leading Stocks
See how NOTV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NOTV Inotiv Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.